Citations

Clear

2358 citation(s) found for "Yu, Long".

Drivers of Diagnostic Variation in a Digital Global Kidney Transplant Reader Study
Hofstraat-Boersma, Rianne, Long, Romy du , Buzzanca, Giorgio , Abiola, Adeyemi A., Albadri, Sam, Ali, Zahabia, Altaleb, Ahmed, Banu, Sultana G., Barry, Marc , Bhalodia, Ami , Bianco, Paola, Broecker, Verena , Buelow, Roman, Cheunsuchon, Boonyarit , Crisi, Giovanna M., Daneshvar, Simin, Dokouhaki, Pouneh, Drachenberg, C., Florquin, Sandrine, Gibson, Ian W., Gujarathi, Saurabh, Hendricks, Allen R. , Islam, Jaynul, Ismail, Wesam, Jagannathan, Geetha , Kläger, Johannes, Krizova, Adriana , Kurien, Anila A., Kwon, Boomi , Ledesma, Felipe L., Martin, Jonne, Mehta, Shweta S., Messias, Nidia , Mignano, Salvatore , Miranda, Monik E., Moeckel, Gilbert, Pala, Chiara, Ranson, Marc A., Rodriguez, A Castell, Rosenberg, Avi, Setty, Suman , Sheaff, M., Soares, Maria F.S., Surintrspanont, Jerasit , Terinte-Balcan, George, Testa, Francesca , Ticas, David O. Hendriquez, Toniolo, Maria F., Midden, Dominique van, Velagapudi, R, Viswanathan, Seethalakshmi , Stillfried, Saskia von, Kalverboer, Nienke , Bruns, Imke B. , Callegaro, Giulia , Vries, A A F De, Peters-Sengers, Hessel, Kers, Jesper, Hofstraat, Rianne , Adefidipe, Adeyemi Abiola, Albadri, Sam , Angioi, Andrea , Banu, Sultana Gulshana, Bianco, Paola, Buelow, Roman David, Chauveau, Bertrand , Chen, Guoli , Crisi, Giovanna Maria, Dendooven, Amélie , Drachenberg, Cinthia Beskow , Farris, Alton B. , Ferlicot, Sophie , Florquin, Sandrine , Fontana, Francesco , Gibier, Jean‐Baptiste , Gibson, Ian W. , Husain, Sufia , Ismail, Wesam, Kläger, Johannes Philipp , Kozakowski, Nicolas , Kurien, Anila Abraham , L’Imperio, Vincenzo , Ledesma, Felipe L , Low, Julia P. , Miranda, Monik Ediana , Price, Brendon , Ranson, Marc Andres, Roelofs, Joris J. T. H. , Sadeghipour, Alireza , Sekulic, Miroslav , Setty, Suman , Soares, Maria Fernanda , Terinte‐Balcan, George , Ticas, David Henriquez, Toniolo, María Fernanda , Midden, Dominique van , Velagapudi, Ramya Krishna , Stillfried, Saskia Freifrau von , Wu, Chih‐Ying , Water, Bob van de , Helm, Danny van der , Sengers, Hessel Peters , Kers, Jesper

Mayo Clinic

No container title available | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.09.26357318 Get It

ABSTRACT Background Diagnostic interpretation of kidney allograft biopsies using the Banff classification remains variable, but the determinants of this variability are not fully defined. We performed a global, fully digital multi-reader study to identify the principal drivers of disagreement in Banff-based assessment. Methods Thirty-six kidney transplant biopsies were independently scored by 67 renal pathologists on a standardized digital platform. Readers assessed Banff lesions on hematoxylin and eosin, periodic acid–Schiff, and Jones’ silver stains; final diagnostic categories were assigned using prespecified Banff-based decision rules. Interobserver agreement was quantified with Gwet’s agreement coefficient (AC) statistics. Determinants of diagnostic agreement were evaluated using pairwise mixed-effects logistic regression, and reader similarity was examined by principal component analysis (PCA) with post hoc molecular annotation. Results Agreement for final diagnostic categories was moderate (Gwet’s AC1, 0.55; 95% CI, 0.47–0.63). Lesion-level agreement varied substantially, with lowest agreement for selected threshold-dependent inflammatory or semi-quantitative lesions, including interstitial inflammation in areas of IFTA, peritubular capillaritis and arteriolar hyalinosis. Diagnostic concordance differed markedly across biopsies, indicating strong case-level heterogeneity. In pairwise models, differences in active inflammatory and vascular lesion scoring were the strongest correlates of diagnostic disagreement; reader experience and geography contributed minimally. Principal component analysis showed reader variation was organized along two dominant axes: a rejection-calling threshold axis linked mainly to tubulointerstitial inflammatory injury, and a T cell-mediated (TCMR/TI) and antibody-mediated/microvascular (AMR/MVI) inflammation-oriented phenotypic classification axis. Conclusion Interobserver variation in Banff-based kidney transplant biopsy assessment is structured rather than random and driven mainly by how readers threshold and integrate key inflammatory lesion compartments rather than experience or geographic location.
Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy
Miner, A, Zetterberg, Henrik, Blennow, Kaj, Groh, Jenna R., Singh, Alpana, Dieckhoff, Kari, Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J. , Bernick, C L, Peskind, Elaine, Asken, Breton M., Tanner, Jeremy A., Rabinovici, Gil D., Banks, Sarah J., Barr, William B., Wethe, Jennifer V., Cantu, Robert C., Dodick, David W., Mez, Jesse, Palmisano, J, Martin, Brett, Stein, Thor D., McKee, Ann C., Cummings, Jeffrey L., Shenton, Martha E., Reiman, E Bieto, Rc, Stern, Ashton, Nicholas J., Alosco, Michael L., Chen, Kewei, Protas, Hillary, Su, Yi, Boker, Connie, Au, Rhoda, Farrer, Lindsay, Helm, Robert, Kowall, Neil, Mercier, Gustavo, Otis, James, Weller, Jason, Bragg, Tahlia, Simkin, Irene, Trujillo-Rodriguez, Diana, Amerongen, Suzan van , Andino, Alondra, Conneely, Shannon, Diamond, Courtney, Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Kossow, Bailey, Kugelmass, Carrie, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen, Nanna, Mary, DiPopolo, Marty, Platt, Taylor, Rice, Fiona, Sestak, Madison, McClean, Michael, Annis, Douglas, Chaisson, Christine, Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Lu, Jun, Ojo, E O, Pine, Brittany, Ramachandran, Janani, Baucom, Zachary, Tuz‐Zahra, Fatima , Yhang, Eukyung , Bouix, Sylvain, Fitzsimmons, Jennifer, Lin, Alexander P., Koerte, Inga K., Pasternak, Ofer, Arciniega, Hector , Billah, Tashrif , Bonke, Elena, Breedlove, Katherine M. , Carrington, Holly, Coello, Eduardo , Coleman, Michael J., John, Omar , Jung, Leonard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schulz, V. D., Silva, Annelise, Vessey, Brynn, Wiegand, Tim L.T, Miller, Jason, Ritter, Aaron , Sabbagh, Marwan, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Jaeson, Long, Rachelle, Nance, Christine, Sandoval, Priscilla, Staples, Miranda, Clark, Emma F., Serrano, Andrew, Geda, Yonas, Duffy, Amy, Falk, Bryce, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Bellgowan, Patrick, GOLDBERG, JUDITH, Joseph, Binu , Kirov, Ivan, Lui, Yvonne, Marmar, Charles, Wisniewski, T R, Al-Kharafi, Alhassan, George, Allan, Hasanaj, Lisena, Martin, Sammie, Riley, Edward, Runge, William, Serrano, Liliana , Iliff, Jeffrey, Li, Gail, Janssen, D, Meabon, James, Piantino, Juan, Schindler, Abigail, Thomas, Ronald, Colasurdo, Elizabeth , Shofer, Jane, Marcus, Daniel S., Gurney, Jenny , Greenwald, Richard, Johnson, Keith A., Singh, Alpana , Singh, Alpana , Miner, Annalise E., Zetterberg, Henrik , Blennow, Kaj , Groh, Jenna R. , Singh, Alpana, Tripodis, Yorghos , Adler, Charles H. , Bernick, Charles , Peskind, Elaine R. , Asken, Breton M. , Rabinovici, Gil D. , Banks, Sarah J. , Barr, William , Wethe, Jennifer V. , Cantu, Robert C. , Dodick, David W. , Mez, Jesse , Stein, Thor D. , McKee, Ann C. , Cummings, Jeffrey L. , Shenton, Martha E. , Reiman, Eric M. , Ashton, Nicholas J. , Alosco, Michael L. , Protas, Hillary , Au, Rhoda, Weller, Jason , Trujillo‐Rodriguez, Diana , Fagle, Tessa, Mariani, Megan, McLaughlin, Kathleen , Pulukuri, Surya Vamsi , Sestak, Madison, McClean, Michael D , Annis, Douglas, Finney, Carolyn, Lu, Jun, Pine, Brittany, Ramachandran, Janani , Baucom, Zachary, Bouix, Sylvain , Koerte, Inga K , Pasternak, Ofer , Bonke, Elena M. , Carrington, Holly , Coleman, Michael J. , Liao, Huijun, Schulz, Vivian, Wiegand, Tim L. T. , II, Robert W. Turner , Marek, Kenneth , Geda, Yonas E. , Howard, Marci, Montague, Michelle, Babcock, Debra, Bellgowan, Patrick S.F. , Kirov, Ivan, George, Allan, Meabon, James S. , Piantino, Juan , Thomas, Ronald G. , Colasurdo, Elizabeth A. , Shofer, Jane, Marcus, Daniel S., Johnson, Keith A.

Mayo Clinic

JAMA Network Open | July 13, 2026 | Volume: 9 | Issue: 7 | Pages: e2622966

10.1001/jamanetworkopen.2026.22966 | PMID 42440317 Get It

Importance In vivo biomarkers for detecting neuropathologies from repetitive head impacts (RHI), including chronic traumatic encephalopathy (CTE), are needed. Objective To evaluate the utility of plasma phosphorylated tau 217 (p-tau217), assess its performance as a beta-amyloid (Aβ) biomarker in participants with RHI exposure at risk for CTE, and explore concordance with CTE neuropathology in a postmortem subsample. Design, Setting, and Participants This longitudinal, multicenter, case-control study used data from the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of CTE (DIAGNOSE CTE) Research Project, collected from September 2016 to October 2023. Participants were former American football players (case participants) and asymptomatic men unexposed to RHI (control participants). A subsample had available neuropathologic data. Exposures RHI, traumatic encephalopathy syndrome (TES) diagnoses, and levels of CTE certainty. Main Outcomes and Measures Plasma p-tau217 (classified as positive [≥0.63 pg/mL], intermediate [0.40-0.62 pg/mL], and negative [<0.40 pg/mL]), Aβ–positron emission tomography (PET; 18 F-florbetapir; with Aβ-positive defined as a standardized uptake value ratio [SUVR] ≥1.10), and tau-PET ( 18 F-flortaucipir). TES diagnoses were assigned by multidisciplinary consensus conference. Analyses of postmortem brains controlled for age, race, and APOE ε4 status. Results Among 231 participants (mean [SD] age, 57.75 [8.25] years), 177 were former football players (117 professional and 60 college) and 54 were unexposed participants. Former football players had higher baseline mean (SD) p-tau217 concentrations than unexposed participants (0.35 [0.26] pg/mL vs 0.27 [0.14] pg/mL; P = .008), although this was driven by a higher proportion of Aβ-PET–positive participants among former players. Plasma p-tau217 increased over time across the sample (B = 0.207 [95% CI, 0.117-0.298]; P < .001), with no significant time × exposure group interactions. Among football players, p-tau217 showed no time × group interactions with TES diagnosis, TES-CTE certainty, or RHI metrics. Higher p-tau217 concentration correlated with higher global Aβ-PET SUVR (B = 0.058 [95% CI, 0.053-3.501; P = .01), with a few discordant cases (5 participants were p-tau217–negative and Aβ-PET–positive; 7 participants were p-tau217–positive and Aβ-PET–negative). P-tau217 had similar areas under the curve for projecting Aβ-PET positivity as cerebrospinal fluid (CSF) p-tau181/Aβ42 and CSF Aβ40/42 measures (p-tau217: AUC, 0.88 [95% CI, 0.80-0.96]; CSF p-tau181/Aβ42: AUC, 0.89 [95% CI, 0.79-1.00]; CSF Aβ40/42: AUC, 0.85 [95% CI, 0.72-0.98]). Among 9 brain donors, 6 had CTE (stages II-IV; none with Alzheimer disease). Seven had negative or intermediate p-tau217, concordant with Aβ-PET. Two p-tau217 outliers with stage III CTE had normal concentrations upon additional testing. Conclusions and Relevance The findings of this study suggest that plasma p-tau217 concentration is unlikely to be useful for the detection of CTE, but it does show utility for ruling out Aβ pathology in participants at risk for CTE.
Reply to: “Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743” and “Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743”
Scherpereel, Arnaud , Mansfield, Aaron S. , Grossi, Francesco , Popat, Sanjay , Baas, Paul , Nowak, Anna K. , Tsao, Anne S. , Fujimoto, Nobukazu , Aragón, Yolanda Bautista, Talbot, Toby, Kaplan, Muhammet A., Soomro, Raheela, Hu, Nan , Ip, Virginia , Peters, Solange , Talbot, Toby , Kowalski, Dariusz , Cardona, Andrés F , Lee, Adam , Hung, Yu-Han , Zalcman, Gérard , Mansfield, Aaron S , Nowak, Anna K , Popat, Sanjay , Baas, Paul , Grossi, Francesco , Tsao, Anne S. , Peters, Solange , Bautista-Aragón, Yolanda, Kowalski, Dariusz M. , Cardona, Andrés F. , Zalcman, Gérard

Mayo Clinic

Journal of Clinical Oncology | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01153 | PMID 42430671 Get It

Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers
Shah, Priyanshi , Peersen, Anina, Sahai, Vaibhav , Mahipal, Amit , Naleid, Nikolas , Borad, Mitesh J. , Bekaii‐Saab, Tanios , Sonbol, Mohamad Bassam , Majeed, Umair , Babiker, Hani M. , O’Donnell, Conor, Malla, Midhun , Conboy, Caitlin B. , Fonkoua, Lionel Kankeu, Washburn, L. , Peterson, Nicole , Carr, Ryan M., Starlinger, P, Smoot, Rory, Warner, Susanne, Ilyas, Sumera L., Heimbach, Julie, Borad, Mitesh J , O'Donnell, Conor D J , Conboy, Caitlin B , Washburn, Leslie A , Halfdanarson, Thorvardur R , Peterson, Nicole , McWilliams, Robert R , Graham, Rondell P , Gores, Gregory J. , Roberts, Lewis R , Ou, Fang-Shu , Tran, Nguyen , Mahipal, Amit , Sonbol, Mohamad B , Bekaii-Saab, Tanios S , Babiker, Hani , Majeed, Umair , Sahai, Vaibhav , Peersen, Anina, Gupta, Garima , Fonkoua, Lionel Aurelien Kankeu , Hálfdánarson, Þorvarður R. , McWilliams, Robert R. , Carr, Ryan M , Graham, Rondell P. , Starlinger, Patrick, Warner, Susanne, Ilyas, Sumera I. , Gores, Gregory J. , Roberts, Lewis R. , Heimbach, Julie K. , Ou, Fang‐Shu , Tran, Nguyen H.

Mayo Clinic

JCO Precision Oncology | July 10, 2026 | Volume: 10 | Issue: 7 | Pages: No page available

10.1200/po-25-01156 | PMID 42430699 Get It

PURPOSE Deficient mismatch repair/microsatellite instability (dMMR, MSI-H) in biliary tract cancers (BTCs) is observed in 1%-5% of tumors. MSI-H across solid tumors has demonstrated durable response to immune checkpoint inhibitors (ICIs) regardless of the anatomic location. Here, we describe clinical outcomes and surgical conversion of MSI-H BTC treated with ICIs. Patients and Methods We conducted a multicenter, retrospective analysis of BTC patients with dMMR/MSI-H between 2017 and 2024 at Mayo Clinic, University of Michigan, and University Hospitals Seidman Cancer Center. Outcomes of interest were surgical resection rate, rate of pathologic response, 2-year overall survival (OS; time from initiation of treatment to death/last follow-up), and time to treatment discontinuation (TTD; time from initiation of treatment to cessation because of any cause). Analyses were descriptive. RESULTS Thirty patients with MSI-H BTC were identified: 19 with cholangiocarcinoma, three with gallbladder cancer, and 8 with BTC undefined. The median age at diagnosis was 61.5 years (range, 26-86). Twenty-six (86.7%) patients had advanced stage at diagnosis. Twenty-seven patients (90%) received first-line systemic therapy, and 13 (48.1%) continued onto second line. Six patients (23.1%) were restaged to resectable from advanced disease after ICI therapy and underwent resection; all remained recurrence-free at last follow-up. Of these six patients, 3 (50%) achieved a pathologic complete response. Among those receiving first-line therapy, the median TTD was 9.9 months (95% CI, 5.7 to 14.5 months) and the 2-year OS was 73% (95% CI, 56% to 94%). CONCLUSION ICI therapy in patients with MSI-H BTC demonstrated durable response and downstaged some BTC to a resectable stage. dMMR/MSI-H should be performed up-front to guide treatment decisions.
Integration and Long-Term Use of the CorTec-BCI2000 Platform in an In Vivo Canine Model
Lampert, F. , Ayyoubi, Amir Hossein , Besheli, Behrang Fazli , Engelhardt, William , Kim, Inyong , Ince, Nuri F., Brunner, Peter, Worrell, Gregory A., Miller, Kai, Mívalt, Filip , Jensen, Michael A. , Ince, Nuri F. , Brunner, Peter , Worrell, Gregory A. , Miller, Kai J.

Mayo Clinic

2025 12th International IEEE/EMBS Conference on Neural Engineering (NER) | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/ner61569.2025.11588913 Get It

Short-Term and Long-Term Opioid Prescribing by Specialty, 2010 to 2024
Heckmann, Rebekah, Ahadpour, Mitra , Hevesi, Sara A., Jeffery, Molly M., Buonora, Michele J. , Starrels, Joanna L. , Hevesi, Sara , Ross, Joseph S. , Jeffery, Molly Moore

Mayo Clinic

JAMA Network Open | July 7, 2026 | Volume: 9 | Issue: 7 | Pages: e2622016

10.1001/jamanetworkopen.2026.22016 | PMID 42412429 Get It

Importance Opioid prescribing has decreased in the US for more than a decade. However, less is known about how prescribing trends differ by prescriber specialty and separately for short-term and long-term opioid prescribing for which the indications, clinical decision-making, and potential for harm vary substantially. Objective To characterize opioid analgesic prescribing trends in the US between January 1, 2010, and December 31, 2024, by prescriber specialty, analyzing short-term and long-term opioid use episodes separately. Design, Setting, and Participants This cross-sectional study used administrative claims data for commercially insured and Medicare Advantage patients (aged ≥65 years and <65 years with long-term disability) with at least 90 days of enrollment in medical and prescription coverage. Statistical analysis was performed from May 2025 to September 2025. Main Outcomes and Measures Prescribing volume, daily dose, and prescription duration. Results The study identified 110 288 218 opioid fills by 14 959 612 patients during the 15-year study period. Among opioid fills, 59.4% were attributed to female patients; the median (IQR) age at opioid fill was 61 (50-71) years. From 2010 to 2024, decreases in opioid prescribing were greater for long-term than short-term opioid use episodes (eg, commercial cohort: 81.3% reduction [from 33.2 fills per 100-person years in 2010 to 6.2 in 2024] and 74.6% reduction [from 36.2 fills per 100-person years in 2010 to 9.2 in 2024]), respectively. The proportion of all opioid fills written by primary care clinicians decreased (eg, Medicare Advantage with disability cohort: from 52.2% to 47.2%), whereas those written by pain medicine specialists increased (eg, Medicare Advantage with disability cohort: from 17.1% to 25.7%). Distinct trends for short-term and long-term opioid use episodes were observed in prescription characteristics, such as daily dose and duration. Conclusions and Relevance In this cross-sectional study of opioid prescribing trends in the US between 2010 and 2024, decreases in prescribing were greatest in long-term opioid use episodes, and prescribing was increasingly concentrated among pain medicine specialists. These findings suggest the need to balance reductions in opioid prescribing with provision of nonopioid pain treatments and raise concerns about access to care for patients taking opioids for chronic pain management.
Patient-Centered Approach to Surgical Prevention of Ovarian Cancer
Lu, Karen H., Chisholm, Gary B. , Peterson, C., Roche, Kara Long , Bakkum-Gamez, Jamie, Feltmate, Colleen, Kim, Sarah, Hagemann, Andrea R. , Carter, Jeanne , Hickey, Martha, Crase, Jamie , Gavin, K, Polinsky, Deborah , D'Andrea, AD, Lu, Karen H. , Norquist, Barbara M. , Bakkum‐Gamez, Jamie N. , Romero, Iris L. , Feltmate, Colleen M. , Levine, Douglas A. , Hickey, Martha , Gavin, Kathleen , D’Andrea, Alan D. , Nebgen, Denise R. , Swisher, Elizabeth M.

Mayo Clinic

JAMA Network Open | July 7, 2026 | Volume: 9 | Issue: 7 | Pages: e2622026

10.1001/jamanetworkopen.2026.22026 | PMID 42412428 Get It

Importance Risk-reducing salpingo-oophorectomy (RRSO) is an effective option to prevent ovarian cancer in high-risk individuals, but adverse effects from premature menopause are a barrier to uptake. Interval salpingectomy with delayed oophorectomy (ISDO) may be an effective alternative. Objective To evaluate the association of ISDO vs RRSO and sexual function and menopausal symptoms. Design, Setting, and Participants This prospective, multicenter, nonrandomized (patient preference) clinical trial was performed among Women Choosing Surgical Prevention participants with a pathogenic or likely pathogenic germline variant conferring an increased risk for ovarian cancer. Patients from 9 US centers were enrolled from June 2, 2016, to October 28, 2020; chose ISDO or RRSO; and were followed up for 24 months. The analysis was performed on November 13, 2024. Interventions Participant-selected RRSO or ISDO. Main Outcomes and Measures Changes in sexual function and menopausal symptoms from baseline to 6, 12, and 24 months. Inverse probability weighting was applied to achieve covariate balance across groups. Results The analytic sample included 334 female participants (mean [95% CI] age at consent, 39.2 [38.7-.9.7] years) who underwent RRSO (n = 165) or ISDO (n = 169) and completed 6-month questionnaires. Significantly more participants experienced clinically meaningful worsening of sexual function at 6 months compared with baseline after RRSO vs ISDO (33.1% [39 of 118] vs 16.8% [17 of 101], respectively; odds ratio, 2.00 [95% CI, 1.20-3.35]) and at 12 months (39.2% [38 of 97] vs 18.3% [17 of 93], respectively; odds ratio, 1.69 [95% CI, 1.09-2.63]). This finding was no longer significant at 24 months. When restricted to the RRSO group who took hormone replacement therapy, there was no significant worsening of total sexual function scores or menopausal symptoms compared with baseline. No interval ovarian cancers were reported. Conclusions and Relevance This nonrandomized clinical trial comparing RRSO with ISDO found that ISDO was less likely to impair sexual function, which addresses an important barrier to surgical prevention in high-risk patients in premenopause. After RRSO, use of hormone replacement therapy mitigated menopausal symptoms and prevented decline in sexual function. More information is needed about the safety of ISDO. Trial Registration ClinicalTrials.gov Identifier: NCT02760849
Prophylactic Antibiotics for Mechanically Ventilated Patients
Long, Brit , Gottlieb, Michael, Gottlieb, Michael

Mayo Clinic

Academic Emergency Medicine | July 7, 2026 | Volume: 33 | Issue: 7 | Pages: No page available

10.1111/acem.70378 | PMID 42411719 Get It

Astrocyte-to-microglia purinergic signaling mediates synaptic shielding and promotes neuronal activity
Haruwaka, Koichiro , Liu, Juan , Liang, Yue, Matsumoto, Shinya , Shi, Wu, Zhao, Shunyi, Xie, Zhongcong, Jing, Miao, Wu, Long-Jun , Haruwaka, Koichiro , Kleidonas, Dimitrios , Liu, Yong , Umpierre, Anthony D. , Jing, Miao , Wu, Long‐Jun

Mayo Clinic

No container title available | July 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.05.735345 | PMID 42427658 Get It

Abstract How glial cells sense and regulate neuronal hypoactivity remains poorly understood. Using in vivo imaging in anesthetized, sleeping, and behaving mice, we identified a glial purinergic signaling mechanism that converts neuronal hypoactivity into local circuit regulation. Cortical hypoactivity increased spatially confined ATP release through astrocytic pannexin-1 hemichannels, which were structurally enriched near perisomatic parvalbumin-positive boutons. Local ATP release directed microglial process movement and stabilized bulbous endings through microglial P2Y12 signaling, accompanied by localized Ca²⁺ activity in microglial processes. Disruption of astrocytic pannexin-1 or microglial P2Y12 impaired bulbous-ending stabilization and abolished rebound increases in neuronal activity during emergence from anesthesia. Similar ATP release and bulbous-ending formation were observed during chemogenetic neuronal silencing or natural sleep in freely behaving mice. These findings identify astrocyte-to-microglia purinergic signaling as a mechanism that converts neuronal hypoactivity into synapse-selective microglial regulation of circuit activity.